Exact Sciences Corp. a yau ya sanar da cewa an buga bayanai daga Rx don Node mai kyau, Endocrine Responsive Breast Cancer, ko RxPONDER, an buga gwajin a cikin New England Journal of Medicine.i Nazarin, wanda mai zaman kansa SWOG Cibiyar Nazarin Ciwon daji ya jagoranta kuma ya dauki nauyin ta. Cibiyar Ciwon Kankara ta Kasa (NCI), ta sami nasarar bayyana fa'idar chemotherapy a farkon matakin, marasa lafiya masu ciwon nono mai kyau tare da Oncotype DX Recurrence Score® sakamakon 0 zuwa 25. Sakamakon farko daga RxPONDER an bayar da rahoton a 2020 San Antonio Cancer Cancer. Taron Taro (SABCS). Yanzu an tabbatar da sakamakon binciken a cikin wannan littafin da aka yi bita da shi.
Mahimmanci, ba a sami fa'idar chemotherapy ba tare da la'akari da adadin nodes ɗin da abin ya shafa, darajar ƙari ko girma. A cikin matan premenopausal tare da nodes masu kyau 1 zuwa 3, an sami fa'idar chemotherapy mai mahimmanci.
Kusan kashi ɗaya bisa uku na marasa lafiya da aka gano tare da mai karɓar hormone (HR) -tabbatacce, HER2-negative farkon ciwon nono yana da ciwace-ciwacen daji wanda ya yada zuwa ƙwayoyin lymph. Yawancin waɗannan marasa lafiya a halin yanzu suna karɓar chemotherapy ko da yake kusan kashi 85% daga cikinsu suna da Sakamakon Makomai na 0 zuwa 25.iii Bugu da kari, kusan biyu daga cikin uku na farkon matakan ciwon nono marasa lafiya sun kasance postmenopausal.iv.
Dangane da sakamakon RxPONDER, National Comprehensive Cancer Network® (NCCN®)v ta sabunta ƙa'idodinta don cutar kansar nono kuma ta gane gwajin Makin Ciwon Nono na Oncotype DX a matsayin kawai gwajin da za a iya amfani da shi don hasashen fa'idar chemotherapy a farkon nono. masu ciwon daji tare da 1 zuwa 3 tabbatacce axillary lymph nodes, ciki har da micrometastases.vi Gwajin Oncotype DX yanzu shine kawai gwajin da aka rarraba a matsayin "wanda aka fi so" tare da mafi girman matakin shaida don kumburi mara kyau da kuma postmenopausal node-positive (1 zuwa 3 tabbatacce nodes). ) marasa lafiya. Bugu da ƙari, NCCN ta ba da shawarar yin la'akari da gwajin don tantance ƙididdiga a cikin marasa lafiya na premenopausal node-positive wadanda ke takarar neman maganin chemotherapy.
Ɗaya daga cikin manyan gwaje-gwaje na asibiti a cikin node-positive, HR-positive, HER2-negative farkon ciwon nono, RxPONDER ya sanya mata fiye da 5,000 tare da ƙananan nodes masu kyau zuwa uku. An gudanar da bincike mai zuwa, bazuwar Mataki na III a wurare 632 a cikin ƙasashe tara - Amurka, Kanada, Mexico, Colombia, Ireland, Faransa, Spain, Koriya ta Kudu da Saudi Arabia. Matan da ke da Sakamakon Matsala na 0 zuwa 25 an bazu su zuwa jiyya tare da maganin hormone kadai ko chemotherapy tare da maganin hormone. An keɓance marasa lafiyar da ba a san su ba bisa ga sakamakon maimaitawar su, matsayin menopause da nau'in tiyatar kumburin lymph. Ana yin ƙarin nazari da ƙarin bin diddigin haƙuri ta masu binciken SWOG.
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Based on the RxPONDER results, the National Comprehensive Cancer Network® (NCCN®)v updated its guidelines for breast cancer and recognized the Oncotype DX Breast Recurrence Score test as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1 to 3 positive axillary lymph nodes, including micrometastases.
- I The study, led by the independent SWOG Cancer Research Network and sponsored by the National Cancer Institute (NCI), successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0 to 25.
- Women with a Recurrence Score result of 0 to 25 were randomized to treatment with hormone therapy alone or chemotherapy followed by hormone therapy.
